만성폐쇄성폐질환(COPD) 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market size is expected to reach USD 45.55 Billion in 2034 from USD 29.31 Billion (2025) growing at a CAGR of 5.02% during 2026-2034.

The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is poised for significant growth as the prevalence of COPD continues to rise globally. COPD is a progressive lung disease characterized by airflow limitation, leading to breathing difficulties and reduced quality of life. The increasing incidence of risk factors such as smoking, air pollution, and occupational exposures is driving the demand for effective COPD treatments, including bronchodilators, corticosteroids, and combination therapies. As healthcare providers seek to improve patient outcomes and manage symptoms, the market for COPD treatments is expected to flourish.

Technological advancements are playing a crucial role in shaping the future of the COPD treatment market. Innovations in drug delivery systems, such as inhalers and nebulizers, are enhancing the efficacy and convenience of COPD therapies. Additionally, the integration of digital health technologies, including mobile applications and remote monitoring devices, is empowering patients to manage their condition more effectively. As manufacturers continue to invest in research and development, the COPD treatment market is likely to see increased adoption of innovative solutions across various healthcare settings.

Moreover, the growing emphasis on patient education and self-management is influencing the COPD treatment market's growth trajectory. As patients become more informed about their condition and treatment options, there is a rising demand for resources and support systems that facilitate effective self-management. This trend is driving collaboration between healthcare providers, pharmaceutical companies, and patient advocacy groups to develop educational initiatives that empower patients to take control of their health. As the market continues to evolve, the integration of technology, patient engagement, and personalized care will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Combination Therapy
• Bronchodilators
• Corticosteroids
• Phosphodiesterase Type 4 Inhibitor
• Mucokinetics
• Others

By Type

• Chronic Bronchitis
• Emphysema

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici Sp A, F HoffmannLa Roche Ltd, GlaxoSmithKiine plc, Kyowa Hakko Kirin, Mylan NV, Novartis AG, Orion Corporation, Sanofi, Sunovion Pharmaceuticals Inc Sumitomo Dainippon Pharma Co Ltd, Teva Pharmaceutical Industries Ltd, Theravance Biopharma, Verona Pharmaceuticals

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Combination Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Bronchodilators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Phosphodiesterase Type 4 Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Mucokinetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Chronic Bronchitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Emphysema Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Type
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Type
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Type
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Type
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Type
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Almirall
  • 9.2.2 AstraZeneca
  • 9.2.3 Boehringer Ingelheim International GmbH
  • 9.2.4 CHIESI Farmaceutici S.P A
  • 9.2.5 F. Hoffmann-La Roche Ltd
  • 9.2.6 GlaxoSmithKiine Plc
  • 9.2.7 Kyowa Hakko Kirin
  • 9.2.8 Mylan NV
  • 9.2.9 Novartis AG
  • 9.2.10 Orion Corporation
  • 9.2.11 Sanofi
  • 9.2.12 Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd)
  • 9.2.13 Teva Pharmaceutical Industries Ltd
  • 9.2.14 Theravance Biopharma
  • 9.2.15 Verona Pharmaceuticals